Sheng-Yu Ku

Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Transcriptional mediators of treatment resistance in lethal prostate cancer”.

Transcriptional mediators of treatment resistance in lethal prostate cancer

Nature Medicine(2021)10.1038/s41591-021-01244-6

N/A

4.8DataRank · unranked

196 citations

Michael S. Cuoco, Jett Crowdis, Alice Bosma-Moody, Zhenwei Zhang, Kevin Bi +35 more

Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer

Nature Cancer(2023)10.1038/s43018-023-00539-6

N/A

3.3DataRank · unranked

113 citations

Yasutaka Yamada, Sheng-Yu Ku, Varadha Balaji Venkadakrishnan, Joshua A. Korsen, Teja Kalidindi +15 more

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer

Nature Communications(2021)10.1038/s41467-021-26612-1

N/A

1.0DataRank · unranked

37 citations

Aashi Chaturvedi, Sarah A. Munro, Samuel P. Pitzen, Alexander Ling, Weijie Zhang +29 more

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

Nature Communications(2024)10.1038/s41467-024-51156-5

N/A

0.928DataRank · unranked

62 citations

Adam Presser, Richa Singh, Matthew A. Booker, Nicole A. Traphagen, Kenny Weng +15 more

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

Nature Communications(2021)10.1038/s41467-021-22139-7

N/A

0.773DataRank · unranked

172 citations

David Y. Takeda, Ji-Heui Seo, Justin H. Hwang, Sheng-Yu Ku, Rand Arafeh +36 more

Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0754

N/A

0.626DataRank · unranked

64 citations

Orsetta Quaini, Kei Mizuno, Francesco Orlando, Yari Ciani, Sheng-Yu Ku +23 more

Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer

Science Translational Medicine(2023)10.1126/scitranslmed.adf6732

N/A

0.598DataRank · unranked

53 citations

Varadha Balaji Venkadakrishnan, Kei Mizuno, Martin Bakht, Sheng-Yu Ku, Maria Mica Garcia +2 more

Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

npj Precision Oncology(2021)10.1038/s41698-021-00211-1

N/A

0.533DataRank · unranked

34 citations

Sheng-Yu Ku, Luisa Fernandez, Angel Dago-Rodriquez, Jerry S. H. Lee, Adam Jendrisak +11 more

Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation

Cancer Cell(2025)10.1016/j.ccell.2025.03.027

N/A

0.489DataRank · unranked

25 citations

Jiacheng Guo, Xin Xu, Xinpei Ci, Yulin Mo, Yakup Kohen +26 more

Genomic and clinical characterization of stromal infiltration markers in prostate cancer

Cancer(2020)10.1002/cncr.32688

N/A

0.406DataRank · unranked

14 citations

Mohammed Alshalalfa, Shuang G. Zhao, Himisha Beltran, William S. Chen, Fallon Chipidza +11 more

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer

Nature Communications(2025)10.1038/s41467-025-60654-z

N/A

0.373DataRank · unranked

11 citations

Sheng-Yu Ku, Varadha Balaji Venkadakrishnan, Martin Bakht, Michael Sigouros, Joanna Chan +18 more

MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy

JCI Insight(2025)10.1172/jci.insight.190924

N/A

0.373DataRank · unranked

11 citations

Tatsuaki Daimon, Hiroshi Hongo, Sheng-Yu Ku, Hiroki Ozawa, Naoki Haratake +14 more

Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad184

N/A

0.345DataRank · unranked

9 citations

Xiaofei Wang, Evan W. Warner, Andrea Sboner, Matti Annala, Michael Sigouros +13 more

The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancer

Scientific Reports(2022)10.1038/s41598-022-21711-5

N/A

0.292DataRank · unranked

6 citations

Shiv Ram Krishn, Khalid Sossey‐Alaoui, Priyanka S. Rana, Elżbieta Pluskota, Pyung Hun Park +17 more

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

Research Square(2024)10.21203/rs.3.rs-3935288/v1

N/A

0.241DataRank · unranked

4 citations

Adam Presser, Richa Singh, Matthew A. Booker, Nicole A. Traphagen, Kenny Weng +15 more

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

Research Square(2024)10.21203/rs.3.rs-3935288/v2

N/A

0.165DataRank · unranked

2 citations

Adam Presser, Richa Singh, Matthew A. Booker, Nicole A. Traphagen, Kenny Weng +15 more

Circulating tumor DNA (ctDNA) to detect neuroendocrine prostate cancer genomic and DNA methylation changes.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.8

N/A

0.165DataRank · unranked

2 citations

Alessandro Romanel, Vincenza Conteduca, Nicola Casiraghi, Michael Sigouros, Gian Marco Franceschini +13 more